Concord Medical Schedules 2025 Annual Meeting of Shareholders
Rhea-AI Summary
Concord Medical (NYSE: CCM) will hold its 2025 annual general meeting of shareholders on December 29, 2025 at 10:00 a.m. Beijing Time at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing.
The shareholder record date is December 19, 2025. No proposals will be submitted for shareholder approval; the meeting is convened for entitled shareholders to discuss company affairs with management.
The company's Form 20-F containing audited financial statements for the year ended December 31, 2024 is available on the company's investor relations website and the SEC website.
Positive
- None.
Negative
- None.
News Market Reaction – CCM
In the Dec 2 session, CCM declined 3.36%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | AGM scheduling | Neutral | -3.4% | Annual meeting date and Form 20-F availability announced without new proposals. |
| Jul 14 | Clinical milestone | Positive | +5.4% | Completion of China’s first proton therapy for choroidal malignant melanoma. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited history shows one positive medical milestone aligning with a price rise and one neutral corporate update coinciding with a decline, suggesting mixed reactions to non-financial news.
Over the past six months, Concord Medical has reported both corporate and operational developments. A July 14, 2025 milestone on China’s first proton therapy for choroidal malignant melanoma coincided with a 5.39% gain, highlighting the market’s sensitivity to clinical achievements. By contrast, a December 2, 2025 notice about scheduling the 2025 annual meeting and access to the 2024 Form 20-F saw a 3.36% decline, suggesting routine governance updates have not consistently supported the share price.
Key Terms
form 20-f regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
No proposal will be submitted for shareholder approval at the Meeting. Instead, the Meeting will be convened for shareholders who are entitled to vote to discuss Company affairs with management. Concord Medical's annual report on Form 20-F filed with the
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
View original content:https://www.prnewswire.com/news-releases/concord-medical-schedules-2025-annual-meeting-of-shareholders-302630224.html
SOURCE Concord Medical Services Holdings Limited